Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

Francesco Orio, Stefano Palomba, Teresa Cascella, Libuse Tauchmanovà, Luciano G. Nardo, Sebastiano Di Biase, Donato Labella, Tiziana Russo, Silvia Savastano, Achille Tolino, Fulvio Zullo, Annamaria Colao, Gaetano Lombardi

Research output: Contribution to journalArticlepeer-review


This study aimed to evaluate plasminogen activator inhibitor-1 (PAI-1) activity in PCOS. Thirty women with PCOS - 15 normal-weight and 15 obese - and 30 healthy women matched as a group for age and body mass index (BMI) were recruited. The homeostasis model assessment (HOMA) score was significantly elevated in obese compared with normal-weight women, in both PCOS women and controls. HOMA score was significantly higher in both PCOS groups relative to controls. After further adjustment for BMI, PAI-1 activity (IU/ml ± SD) was significantly higher in the PCOS groups compared with controls. A significant positive correlation was found between HOMA score and BMI in PCOS and control groups. Serum PAI-1 activity was significantly related to BMI and HOMA score. When considering two BMI subgroups, there was no significant difference in the relationship between serum PAI-1 activity and HOMA score in both the control and PCOS groups. No other significant relationship was found between serum PAI-1 activity and any other hormonal or metabolic parameter. In conclusion, women with PCOS have significantly elevated PAI-1 activity independent of obesity, and it is speculated that elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in PCOS.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalReproductive BioMedicine Online
Issue number5
Publication statusPublished - Nov 2004


  • Cardiovascular risk
  • Insulin resistance
  • PAI-1 activity
  • Polycystic ovary syndrome (PCOS)

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?'. Together they form a unique fingerprint.

Cite this